|Jeffrey Whiteaker, Ph.D., is currently Director of Proteomics in the laboratory of Mandy Paulovich at the Fred Hutchinson Cancer Research Center in Seattle, WA. Originally from Arizona, he received a B.S. in Chemistry at the University of Arizona and obtained a PhD from the University of California at Riverside. He pursued post-doctoral research at the University of Maryland in the laboratory of Catherine Fenselau. He has been in the Pacific Northwest since 2004, where his current research focuses on using proteomic techniques to discover and validate biomarkers related to cancer.
Developing quantitative assays for biomarker developmentIncreasingly, selected/multiple reaction monitoring (SRM/MRM) is being implemented for quantitative targeted proteomics; however, sensitivity remains a limiting factor in analyzing low abundance proteins. To address this limitation, we have developed immuno-MRM assays using stable isotope standards with capture by anti-peptide antibodies (SISCAPA) coupled with mass spectrometry. This presentation will focus on the use of Skyline in development of highly multiplexed assays, evaluation of interlaboratory assay performance, standardization of analysis procedures, and implementation of assays on multiple vendor platforms.